[Federal Register Volume 87, Number 42 (Thursday, March 3, 2022)]
[Notices]
[Pages 12207-12208]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2022-04463]


=======================================================================
-----------------------------------------------------------------------

NUCLEAR REGULATORY COMMISSION


Advisory Committee on the Medical Uses of Isotopes: Charter 
Renewal

AGENCY: U.S. Nuclear Regulatory Commission.

ACTION: Notice of charter renewal.

-----------------------------------------------------------------------

SUMMARY: The U.S. Nuclear Regulatory Commission (NRC) has determined 
that renewal of the charter for the Advisory Committee of the Medical 
Uses of Isotopes (ACMUI) until February 28, 2024, is in the public 
interest in connection with duties imposed on the Commission by law. 
This action is being taken in accordance with the Federal Advisory 
Committee Act, after consultation with the Committee Management 
Secretariat, General Services Administration.

FOR FURTHER INFORMATION CONTACT: Donald Lowman, Office of Nuclear 
Material Safety and Safeguards, U.S. Nuclear Regulatory Commission, 
Washington, DC 20555; Telephone: (301) 415-5452 or at 
<a href="/cdn-cgi/l/email-protection#490d262728252d6705263e24282709273b2a672e263f"><span class="__cf_email__" data-cfemail="7b3f14151a171f5537140c161a153b150918551c140d">[email protected]</span></a>.

SUPPLEMENTARY INFORMATION: The purpose of the ACMUI is to provide 
advice to the NRC on policy and technical issues that arise in 
regulating

[[Page 12208]]

the medical use of byproduct material for diagnosis and therapy. 
Responsibilities include providing guidance and comments on current and 
proposed NRC regulations and regulatory guidance concerning medical 
use; evaluating certain non-routine uses of byproduct material for 
medical use; and evaluating training and experience of proposed 
authorized users. The members are involved in preliminary discussions 
of major issues in determining the need for changes in NRC policy and 
regulation to ensure the continued safe use of byproduct material. Each 
member provides technical assistance in his/her specific area(s) of 
expertise, particularly with respect to emerging technologies. Members 
also provide guidance as to NRC's role in relation to the 
responsibilities of other Federal agencies as well as of various 
professional organizations and boards.
    Members of this Committee have demonstrated professional 
qualifications and expertise in both scientific and non-scientific 
disciplines including nuclear medicine; nuclear cardiology; radiation 
therapy; medical physics; nuclear pharmacy; State medical regulation; 
patient's rights and care; health care administration; and Food and 
Drug Administration regulation.

    Dated at Rockville, Maryland, this 28th day of February, 2022.

    For the U.S. Nuclear Regulatory Commission.
Russell E. Chazell,
Federal Advisory Committee Management Officer.
[FR Doc. 2022-04463 Filed 3-2-22; 8:45 am]
BILLING CODE 7590-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>